Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients

Arthritis Care and Research

Volumn 67, Issue 5, 2015, Pages 624-632

  Zhang, Jie ^a   Xie, Fenglong ^a   Delzell, Elizabeth ^a   Yun, Huifeng ^a   Lewis, James D ^b,c   Haynes, Kevin ^b,c   Chen, Lang ^a   Beukelman, Timothy ^a   Saag, Kenneth G ^a   Curtis, Jeffrey R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HEALTHCORE INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLATE MOFETIL; PENICILLAMINE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; AGE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG SELF ADMINISTRATION; FACTUAL DATABASE; IMMUNOLOGY; INJECTION; KAPLAN MEIER METHOD; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADALIMUMAB; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; INJECTIONS; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SELF ADMINISTRATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84928559974     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22510     Document Type: Article

References (35)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum 2012; 64: 2824-35.
3. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, et al. Validation of the methotrexate-first strategy in patients with early poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 2013; 65: 1985-94.
4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
5. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
6. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
7. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
8. Krieckaert CL, Nurmohamed MT, Wolbink GJ., Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner [letter]. Ann Rheum Dis 2012; 71: 1914-5.
9. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
10. Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, et al. Trends in the use of biologic therapies among rheumatoid arthritis patients enrolled in the US Medicare program. Arthritis Care Res (Hoboken) 2013; 65: 1743-51.
11. Emery P, Sebba A, Huizinga TW., Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1897-904.
12. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-29.
13. Centers for Medicare & Medicaid Services. Medicare enrollment, aged beneficiaries as of July 2006. URL: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareEnrpts/downloads/06Aged.pdf.
14. Curtis JR, Xie F, Chen R, Chen L, Kilgore ML, Lewis JD, et al. Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. Pharmacoepidemiol Drug Saf 2013; 22: 1214-21.
15. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009; 15: 457-64.
16. Ray WA., Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
17. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
18. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
19. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
20. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ., Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
21. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
22. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
23. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 531-5.
24. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.
25. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G., Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012; 64: 3850-5.
26. Tang B, Rahman M, Waters HC, Callegari P., Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008; 30: 1375-84.
27. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
28. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
29. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
30. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R., Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008; 59: 1519-26.
31. DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F., Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006; 166: 57-63.
32. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO III, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58: 1921-30.
33. Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, et al. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provide no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum 2011; 63: 2203-8.
34. Fleischmann RM, Kivitz A, van Vollenhoven RF, Shaw JW, Florentinus S, Karunaratne M, et al. No differences in patient-reported outcomes by methotrexate dose among early rheumatoid arthritis patients treated concomitantly with adalimumab: results from the CONCERTO trial. Ann Rheum Dis 2013; 72 Suppl 3: 580.
35. Klabunde CN, Potosky AL, Legler JM, Warren JL., Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-67.